Effect of Secondary Prophylaxis on the Risk of Recurrent Cytomegalovirus Infection Among Solid Organ Transplant Recipients (WTC 2025) - Jul 30, 2025 - Abstract #OA04.8; Pres time: Aug 3, 2025; 05:35 PM - 05:42 PM; Location: Room 4; "Secondary prophylaxis was mostly valganciclovir (N=114, 91.2%), though 9 (7.2%) received letermovir and 2 (1.6%) received maribavir. Solid organ transplant recipients who received secondary prophylaxis had a lower risk of rcsCMVi. Secondary prophylaxis should be considered among patients at high risk for recurrent CMV."
Clinical • Cytomegalovirus Infection • Infectious Disease • Solid Organ Transplantation • Transplantation
|
|
M. Vega Brizneda 1; A. Khazan 1; D. Newell 2; H. Wang 3; C. Koval 1; Z. A. Yetmar 1
|